FendX to Present at the Hidden Gems Conference and Available for Investor Meetings
- Investors have the opportunity to meet FendX CEO Dr. Carolyn Myers at the Hidden Gems Conference.
- The amendment agreement with Capital Analytica extends the term of the agreement from 6 months to 9 months at no additional cost.
- None.
Oakville, Ontario--(Newsfile Corp. - October 18, 2023) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings to reduce the spread of pathogens, announces its participation in the Hidden Gems Conference in New York, NY, and the opportunity for investors to meet the FendX CEO, Dr. Carolyn Myers for one-on-one meetings on October 26, 2023.
Dr. Carolyn Myers will be speaking at the Hidden Gems Conference that will be held at @Ease605, 605 3rd Avenue, New York, NY. In addition, Dr. Carolyn Myers will be available for one-on-one investor meetings. This will be an opportunity for investors to engage directly with the Company on its nanotechnology development and commercialization plans.
"We look forward to presenting FendX's story at the Hidden Gems Conference which provides another opportunity to share the progress we are making with our products under development using our nanotechnology" stated Dr. Carolyn Myers, President and CEO of FendX.
The Company also announces that it has entered into an amendment agreement with Triomphe Holdings Ltd. (DBA Capital Analytica) ("Capital Analytica") dated October 17, 2023 which amends the agreement between the Company and Capital Analytica dated March 21, 2023, which was announced by the Company in its news release dated March 21, 2023. The amendment agreement extends the term of the agreement from 6 months to 9 months from the effective date of March 21, 2023 at no additional cost.
About FendX Technologies Inc.
FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.
ON BEHALF OF THE BOARD
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
Alyssa Barry, Investor Relations
1-833-947-5227
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the Company's belief that REPELWRAP™ will have applications in healthcare settings and other industries; products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company's public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company's such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/184331
FAQ
What conference is FendX participating in?
Who will be available for one-on-one investor meetings?
What is the amendment agreement with Capital Analytica about?
Is there any additional cost associated with the amendment agreement?
